BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Phase 2
Completed
- Conditions
- Heart Failure
- Interventions
- Drug: Neladenoson bialanate (BAY1067197)Drug: Placebo
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 305
- Registration Number
- NCT03098979
- Locations
- 🇺🇸
BryanLGH Medical Center East, Lincoln, Nebraska, United States
🇬🇷General Hospital of Chalkida, Chalkida, Greece
🇦🇹Krankenhaus der Elisabethinen Linz GmbH, Linz, Oberösterreich, Austria
Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT03092999
- Locations
- 🇩🇪
Universitätsklinikum Schleswig-Holstein / AÖR, Lübeck, Germany
🇩🇪CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet
Phase 1
Completed
- Conditions
- Clinical Pharmacology
- Interventions
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2017-03-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 20
- Registration Number
- NCT03074058
LCS16 vs. COC User Satisfaction and Tolerability Study
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: Levonorgestrel (Kyleena, BAY86-5028)Drug: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)
- First Posted Date
- 2017-03-08
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 145
- Registration Number
- NCT03074045
- Locations
- 🇷🇺
Scientific Center of family health & human reprod. problems, Irkutsk, Russian Federation
🇷🇺Altai State Medical University, Barnaul, Russian Federation
🇷🇺Medical Center "Avicenna", Novosibirsk, Russian Federation
Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets
Phase 1
Completed
- Conditions
- Pain
- Interventions
- Drug: Acetylsalicylic acid (Aspirin, BAY1019036)
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 38
- Registration Number
- NCT03056703
First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845
Phase 1
Completed
- Conditions
- Pelvic Inflammatory Disease
- Interventions
- Drug: PlaceboDrug: BAY1834845
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 70
- Registration Number
- NCT03054402
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction
Phase 1
Completed
- Conditions
- Biological Availability
- Interventions
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2018-07-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT03048110
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion
- Conditions
- Tumors Harboring NTRK Fusion
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2019-12-19
- Lead Sponsor
- Bayer
- Registration Number
- NCT03025360
Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: BAY987517Drug: BullFrog Gel Sunscreen Land Sport SPF-50
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT03012347
Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821/2016)
Not Applicable
Completed
- Conditions
- Sunscreening Agents
- Interventions
- Drug: BAY987517
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 17
- Registration Number
- NCT03002922
- Locations
- 🇺🇸
Hill Top Research, Saint Petersburg, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath